OS among patients with AML with relapsed disease by initial CR duration and transplantation status after uproleselan in combination with chemotherapy. Patients with an initial CR duration of <12 months or ≥12 months (A), and patients who underwent transplantation after uproleselan at 10 mg/kg plus MEC and those who did not undergo transplantation after treatment (B). MEC, mitoxantrone/etoposide/cytarabine; NA, not applicable; RP2D, recommended phase 2 dose.